Brief: InhalerX Says Linlithgow Family Office Agreed To Provide A$12.6 Mln In Additional Funding
04/12/2025 01:13
Dec 4 (Reuters) - Inhalerx Ltd IRX.AX: LINLITHGOW FAMILY OFFICE AGREED TO PROVIDE A$12.6 MILLION IN ADDITIONAL FUNDING TO SUPPORT DEVELOPMENT OF SRX-25 Further company coverage: IRX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalis Therapeutics
See all newsBrief: Nexalis Therapeutics Says Sean Williams Has Resigned As Non-Executive Chairman
Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
Brief: Nexalis Therapeutics Seeks Trading Halt
Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
Australia's Nexalis Therapeutics gains most in over 6 months on trial approval